

For release to Journalist and the Financial and Business sector

**BioSpec Global Solutions Inc announces new project development for the testing method for the enumeration of Coliphage virus in drinking water.**

New York, Montreal , September 8, 2009 BioSpec Global Solutions Inc., and partner –ICBS Ltd. (OTCPK: [ICBT](#)), announced today a new project development of a method for the enumeration of Coliphage virus in drinking water.

The development include the building of hardware and optical system. Software and methodologies for simultaneous detection and enumeration of the above virus in drinking water . TOGS 9000 model will be a method for the enumeration of total Coliphage virus in fresh water testing.

“Moving forward with our new R&D projects will allow the company to develop a wide range of testing procedures for the TOGS 9000 units. The TOGS 9000 allows 100% accuracy test results in hours versus days in a conventional laboratory.” Said Don Saunders President and CEO BioSpec Global Solutions. “Without constant and proper testing there is always a health concern as water, whether it be drinking water or recreational water can become contaminated quickly with disease following just as fast. The World Health Organization has set standards for these indicator organisms that have been adopted by most countries around the world.”

Recent studies have shown that the fecal indicator bacteria (FIB) currently used to indicate water quality in the coastal environment may be inadequate to reflect human viral contamination. Coliphage was suggested as a better indicator of human viral pollution and was proposed by the U.S. EPA as an alternative indicator for fecal pollution in groundwater.

The Pro3000™ has been verified by Ryerson University, Agriculture Canada and Saskatchewan Department of Health. It has been accepted for use for drinking water analysis by EPA in the USA when used in conjunction with an EPA approved reagent The TOGS 9000 and 3000 have been used in a research project by the World Health Organization in Hawaii and by OCETA in India.

The company holds worldwide patents on the TOGS 3000 and 9000.

SOURCE: BioSpec Global Solutions Inc. [www.biospecglobal.com](http://www.biospecglobal.com)

CONTACT: Don Saunders, President & CEO

TELEPHONE: 514-932-4402

[www.icbs.ca](http://www.icbs.ca)

NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements

as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.